NPI registry status
Active
2026 NPPES data Pulmonary Disease Physician NPI 1609867142 M.D.
Verify on CMS → Michael Barkoviak, M.D.
Pulmonary Disease Physician in Saint Louis, Missouri.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 9,647 in Pulmonary Disease Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
4K
Medicare Part D claims · 620 beneficiaries · Pulmonary Disease Physician avg: 1K
Generic prescribing
36%
generic claims · 64% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$2.2K
124 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Michael Barkoviak, M.D. filed 4,132 Medicare Part D claims in 2024 as a Pulmonary Disease Physician in Saint Louis, Missouri, prescribing 36% generic.
- 4K
- Part D claims, 2024
- 36%
- generic prescribing
- Likely
- board-certified (heuristic)
- ≥92nd
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Michael Barkoviak, M.D.
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1609867142), first enumerated 11/03/2005.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 4,132 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
2 CMS Care Compare hospital affiliations on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Reported
Industry payment transparency
$2.2K in reported industry payments (124 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1609867142 · Pulmonary Disease Physician
NPI-10 · ENUM-LEGACY · TAX-MID · RX-MID · BOOK-THIN · PHOTO-ENUM
- NPI-10 1609867142
- ENUM-LEGACY 2005
- TAX-MID 10K Pulmonary Disease
- RX-MID 4,132
- BOOK-THIN 225 in Missouri
- PHOTO-ENUM Vikram Dhawan · 2005
Michael Barkoviak, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
4,132 ≥ 92nd percentile 92% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
✓
Board certification likely (heuristic, not verified)
Michael Barkoviak, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 2 hospital affiliations - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Michael Barkoviak, M.D.?
Quality data not reportedPrimary specialty
Pulmonary Disease Physician
Medicare Part D claims
4,132 176% vs specialty avg
Specialty distribution in Missouri
How Pulmonary Disease Physician compares to other specialties among Missouri providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Pulmonary Disease Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1609867142 |
|---|---|
| Specialty | Pulmonary Disease Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 11/03/2005 |
Hospital and facility affiliations
Facilities where Michael Barkoviak, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Pulmonary Consultants Inc
Saint Peters, MO
Sparta Community Hospital D/B/A Quality Healthcare Clinics
Sparta, IL
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Michael Barkoviak, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$2.2K
Largest payer
GlaxoSmithKline, LLC.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Brand-heavy
Michael Barkoviak, M.D. - brand share 64.0%
Pulmonary Disease Physician average
64% brand-name claims vs 36% generic, on 4,132 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
4,132
Total Claims
$2.2M
Total Drug Cost
620
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 5,461.5
- Total Day Supply
- 146,099
- Brand vs Generic
- 64% brand / 36% generic
- Brand Drug Cost
- $2.1M
- Generic Drug Cost
- $46K
- Antibiotic Claims
- 133
Patient Demographics
- Average Patient Age
- 70.7 years
- Avg HCC Risk Score
- 2.05
- Gender Split
- 60% female / 40% male
- Age Distribution
- <65: 129, 65-74: 268, 75-84: 175, 85+: 48
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Michael Barkoviak, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Trelegy Ellipta
Trelegy Ellipta
744 claims
- Albuterol Sulfate …
Albuterol Sulfate Hfa
660 claims
- Prednisone
Prednisone
339 claims
- Anoro Ellipta 228
Anoro Ellipta
228 claims
- Breo Ellipta 217
Breo Ellipta
217 claims
- Breztri Aerosphere 206
Breztri Aerosphere
206 claims
- Montelukast Sodium 204
Montelukast Sodium
204 claims
- Symbicort 132
Symbicort
132 claims
| Drug | Claims |
|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 744 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 660 |
| Prednisone | 339 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 228 |
| Breo Ellipta Fluticasone/Vilanterol | 217 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 206 |
| Montelukast Sodium | 204 |
| Symbicort Budesonide/Formoterol Fumarate | 132 |
| Fluticasone Propionate | 126 |
| Ventolin Hfa Albuterol Sulfate | 100 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pulmonary Disease Physician Overview
How Michael Barkoviak, M.D. fits within the Pulmonary Disease Physician landscape nationally.
9,647
Pulmonary Disease Physician Providers in US
53
States with Pulmonary Disease Physician
1,498
Avg Claims per Provider
Michael Barkoviak, M.D.'s 4,132 claims are above the specialty average of 1,498.
Nationwide Pulmonary Disease Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Barkoviak, both outside Missouri so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2005)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Pulmonary Disease Physician Providers in Missouri
Other clinicians with the same primary specialty enrolled in Missouri, drawn from the same CMS NPPES roster as Barkoviak.
One of 225 Pulmonary Disease Physician providers enrolled in Missouri, 5 are shown here.
Dr. Asem Abdeljalil
M.D.
Kansas City, MO
Dr. Mohannad Abu Omar
M.D
Saint Joseph, MO
Dr. Tareq Abu Salah
M.D.
Columbia, MO
Dr. Adetayo Ademuyiwa
M.D.
St Louis, MO
Dr. Hamna Ahmad
M.D.
Kansas City, MO
Compare Pulmonary Disease Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Michael Barkoviak, M.D.'s specialty? ▼
Michael Barkoviak, M.D. specializes in Pulmonary Disease Physician and practices in Saint Louis, Missouri. Credentials: M.D..
How much does Michael Barkoviak, M.D. prescribe under Medicare Part D? ▼
In 2024, Michael Barkoviak, M.D. wrote 4,132 Medicare Part D claims totaling $2.2M in drug costs for 620 beneficiaries.
Where is Michael Barkoviak, M.D. located? ▼
Michael Barkoviak, M.D. is located at 11133 DUNN RD, Saint Louis, MO, 63136. Phone: (314) 653-5007.
What is Michael Barkoviak, M.D.'s NPI number? ▼
Michael Barkoviak, M.D.'s National Provider Identifier (NPI) is 1609867142, issued on 11/03/2005.
Does Michael Barkoviak, M.D. prescribe more brand-name or generic drugs? ▼
Michael Barkoviak, M.D.'s prescribing is 64% brand-name and 36% generic drugs by claim count, with $2.1M in brand drug costs.
How many Pulmonary Disease Physician providers are there in the US? ▼
There are 9,647 Pulmonary Disease Physician providers across 53 states in the US. The average Pulmonary Disease Physician provider writes 1,498 Medicare Part D claims per year.
What drugs does Michael Barkoviak, M.D. prescribe most often? ▼
Based on 2024 Medicare Part D data, Michael Barkoviak, M.D.'s most frequently prescribed drugs include Trelegy Ellipta, Albuterol Sulfate Hfa, Prednisone. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Michael Barkoviak, M.D. accept Medicare? ▼
Michael Barkoviak, M.D. appears in CMS Medicare data with 4,132 Part D claims and 620 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Michael Barkoviak, M.D.'s credentials? ▼
Michael Barkoviak, M.D.'s NPI is 1609867142 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.